Clinical Trial Update: Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 trial of brentuximab vedotin combined with RCHOP or RCHP in first-line diffuse large B-cell lymphoma was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Seagen Inc. | Conditions: Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse | Phase 2 | Status: TERMINATED | Results posted: 2018-06-21